Efficacy of Aliskiren for Patients with Hypertension Receiving Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin-Receptor Blockers

There are some reports suggesting that the direct renin inhibitor aliskiren may increase the risk of severe hyperkalemia or acute kidney injury when prescribed with angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin-receptor blockers (ARBs). On the other hand, some clinical trials have shown that aliskiren lowers blood pressure in combination with ACE-Is or ARBs. The aim of this cohort study was to investigate the efficacy of aliskiren for patients with hypertension receiving ACE-Is and/or ARBs.